This story has been updated with new information from a letter released today from Origin Technologies to Affymetrix demonstrating an increased financing committment and adressing other concerns.

NEW YORK (GenomeWeb) – An offer by former Affymetrix executives to buy the company under a newly formed shell corporation — and to pay off the cancellation penalties of Thermo Fisher Scientific's previously announced proposal to acquire Affy — has triggered a call and response between Affy, Thermo, and the newcomer Origin Technologies this week.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.